CYTOKINETICS, INCORPORATED

Public Equity (NASDAQ)BiotechnologyPublic CompanyCardiovascular

📍 South San Francisco, California, United States• Founded 1998

StreetZero Signal 57

Be the first to signal interest

About CYTOKINETICS, INCORPORATED

Cytokinetics, Incorporated is a specialty cardiovascular biopharmaceutical company focused on muscle biology. It has over 25 years of scientific innovation and is advancing a pipeline of potential medicines for cardiac muscle dysfunction. Its approved product MYQORZO® (aficamten) treats symptomatic obstructive hypertrophic cardiomyopathy in the U.S., Europe, and China. The company is publicly traded on NASDAQ under CYTK and headquartered in South San Francisco, California.

LATEST FUNDINGRule 144

$268K

Announced 2026-11-09

TOTAL RAISED3.21B USD

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for CYTOKINETICS, INCORPORATED.

Create free account Sign in

Free plan includes 3 full deal profiles every month.

IN THE NEWS

EMPLOYEES—

FOUNDED1998

HQSouth San Francisco, California, United States

Industry

Public Equity (NASDAQ)

Investors

Vulcan Royalty Pharma Deerfield Bosch Capital Sevin Rosen Funds Mayfield Fund Duke University Red Abbey Venture Partners

Key highlights

Public company on NASDAQ (CYTK) with total funding of 3.21B USD.
Recently closed an 805M USD public offering of common stock.
Lead product aficamten approved in multiple regions for obstructive HCM.
Focuses on muscle biology for cardiac dysfunction treatments.
Headquartered in South San Francisco with LinkedIn presence of over 48k followers.